{
  "pmcid": "6019117",
  "sha256": "54e58f85ba9ceb477f63f6974a0e2e68993157fd6c1c7fa801e2cb9fd5070ef1",
  "timestamp_utc": "2025-11-09T22:48:56.866919+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.812036474164138,
    "reading_ease": 19.955000000000013,
    "word_count": 188
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "CHAMP: A Randomised Controlled Trial of Mesenchymal Stromal Cells in Critical Limb Ischemia"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In this phase I/II trial, 32 extremities with CLI requiring BKA were randomised"
      },
      "Participants": {
        "score": 1,
        "evidence": "CLI patients requiring below-knee amputation (BKA)"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive intramuscular injections of allogeneic MSCs (n=16) or autogenous concentrated bone marrow aspirate (cBMA, n=16)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the safety and therapeutic mechanisms of mesenchymal stromal cells (MSC) in CLI patients"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was proangiogenic cytokine expression, measured at the time of amputation."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, with allocation concealment ensured by sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "32 extremities with CLI requiring BKA were randomised"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Ten patients have been treated per protocol."
      },
      "Result_Outcome": {
        "score": 1,
        "evidence": "Preliminary results indicate potential efficacy in proangiogenic cytokine expression."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were monitored, with no severe events reported thus far."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [Trial registration number]."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [Source of funding]."
      }
    },
    "total_score": 15,
    "max_score": 25
  }
}